Clinical Trial

A Potential New Option for Targeted Treatment of Pancreatic Cancer is on the Horizon

TIGeR-PaC is Enrolling Patients Across the Country

The TIGeR-PaC clinical trial is currently enrolling newly-diagnosed locally advanced pancreatic cancer patients. TIGeR-PaC is a randomized study of Trans-Arterial Micro-Perfusion (TAMP) versus systemic chemotherapy. The goal of the trial is to prove extended median survival and improved quality of life through targeted delivery of therapy.

Are you a candidate?

Candidate patients must meet the following criteria:

  • Histologically-confirmed pancreatic cancer with initial diagnosis within 6 weeks of consent
  • Not a candidate for surgery
  • No prior therapy for pancreatic cancer

If you meet the criteria or have questions about the TIGeR-PaC trial, contact RenovoRx. For more information visit

Active Clinical Sites

United States
  • Use  to zoom in and out on the map.
  • Use  by clicking with your cursor and holding down to move map to view locations.
  • Click on  to hide the list of cities.
  • Click on individual cities in the list to remove their location pins from the map.
  • Click on individual pins on the map to view site details

Increasing Published Research Demonstrates RenovoCath’s Utility for Targeted Treatment of Pancreatic Cancer with Improved Safety and Survival